ViroPharma / Chiron / European Scientific Working Group / Roche / GlaxoSmithKline / Wyeth / Professors Karl Nicholson Ab / Aventis Pasteur / /
Continent
Europe / /
Country
Netherlands / Australia / United Kingdom / New Zealand / United States / / /
Event
FDA Phase / Funding / /
Facility
University of British Columbia / Stanford University / Institute of Medicine / Geneva headquarters / Robert Koch Institute / Swedish Institute / Max Planck Institute / WHO National Influenza Centre / Erasmus University / Leicester University / /
IndustryTerm
pharmaceutical industry / medical and pharmaceutical students / pharmaceutical companies producing antivirals / travel sponsorship / pharmaceutical / public health services / pharmaceutical firms / /
World Health Organization / Leicester University / Belgian government / Bureau of Investigative Journalism / WHO National Influenza Centre Rotterdam / European Parliament / Max Planck Institute in Germany / European Centre for Disease Prevention and Control / Erasmus University in the Netherlands / Department of Pharmacology and Therapeutics / WHO Division of Viral Diseases / Swedish Institute for Infectious Disease / European Union / Medicines Agency In Europe / Swedish Institute for Infectious Disease Control / Council of Europe / European Medicines Agency In Europe / Europe Parliamentary Assembly / Food and Drug Administration / Institute of Medicine / British MP / Emergency Committee / Robert Koch Institute / Committee for Medicinal Products for Human Use / Preparedness and Response Unit / Centre for Adaptive Behaviour and Cognition / Centers for Disease Control and Prevention / European Medicines Agency / US Food and Drug Administration / Stanford University / Belgian Ministry of Public Health / University of British Columbia / /
Earlier this year at a speech at the CDC in Atlanta, Dr Margaret Chan, the director general of the WHO, said: WHO anticipated